



Corrigendum: Randomized, Double Blind, Placebo Controlled, Clinical Trial to Study Ashwagandha Administration in Participants Vaccinated Against COVID-19 on Safety, Immunogenicity, and Protection With COVID-19 Vaccine—A Study Protocol

Arvind Chopra¹, Preeti Chavan-Gautam², Girish Tillu², Manjit Saluja¹, Swapnil Borse², Sanjeev Sarmukaddam¹, Susmita Chaudhuri³, BCS Rao⁴, Babita Yadav⁴, Narayanam Srikanth⁴ and Bhushan Patwardhan^{2*}

¹ Center for Rheumatic Diseases, Pune, India, ² Center for Complementary and Integrative Health, Interdisciplinary School of Health Sciences, Savitribai Phule Pune University, Pune, India, ³ Translational Health Science and Technology Institute (THSTI), Faridabad, India, ⁴ Central Council for Research in Ayurvedic Science, New Delhi, India

OPEN ACCESS

Edited and reviewed by:

Zisis Kozlakidis,
International Agency for Research on
Cancer (IARC), France

*Correspondence:

Bhushan Patwardhan
bpatwardhan@gmail.com

Specialty section:

This article was submitted to
Infectious Diseases – Surveillance,
Prevention and Treatment,
a section of the journal
Frontiers in Medicine

Received: 03 March 2022

Accepted: 09 March 2022

Published: 29 March 2022

Citation:

Chopra A, Chavan-Gautam P, Tillu G, Saluja M, Borse S, Sarmukaddam S, Chaudhuri S, Rao BCS, Yadav B, Srikanth N and Patwardhan B (2022) Corrigendum: Randomized, Double Blind, Placebo Controlled, Clinical Trial to Study Ashwagandha Administration in Participants Vaccinated Against COVID-19 on Safety, Immunogenicity, and Protection With COVID-19 Vaccine—A Study Protocol. *Front. Med.* 9:888928. doi: 10.3389/fmed.2022.888928

Keywords: COVID-19, immunogenicity, *Withania somnifera*, vaccine, Ayurveda, Ashwagandha, immunoadjuvant

A Corrigendum on

Randomized, Double Blind, Placebo Controlled, Clinical Trial to Study Ashwagandha Administration in Participants Vaccinated Against COVID-19 on Safety, Immunogenicity, and Protection With COVID-19 Vaccine—A Study Protocol

by Chopra, A., Chavan-Gautam, P., Tillu, G., Saluja, M., Borse, S., Sarmukaddam, S., Chaudhuri, S., Rao, B. C. S., Yadav, B., Srikanth, N., and Patwardhan, B. (2022). *Front. Med.* 9:761655. doi: 10.3389/fmed.2022.761655

In the original article, there was an error in the sentence “One tablet of Ashwagandha or placebo will be administered twice daily (on empty stomach in the morning and after dinner) with water.”

The correction has been made to the **Eligibility** section, “*Trial Intervention*” sub section and the corrected sentence appears below:

“One tablet of Ashwagandha or placebo will be administered daily (on empty stomach in the morning) with water.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Chopra, Chavan-Gautam, Tillu, Saluja, Borse, Sarmukaddam, Chaudhuri, Rao, Yadav, Srikanth and Patwardhan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.